Table 2 Resistance rates of commensal Neisseria species to the tested antimicrobials, interpreted by CLSI and EUCAST breakpoints for Neisseria gonorrheae.

From: Carriage and antimicrobial susceptibility of commensal Neisseria species from the human oropharynx

 

CLSI NR/NT (%)

PEN

CRO

CFX

CIP

TET

AZI*

GEN§

Breakpoint (R >)

1

0.25

0.25

0.5

1

1

16

Overall

27/101 (26.7%)

5/100

(5%)

4/92 (4.3%)

15/92 (16.3%)

21/92 (22.8%)

27/92 (29.3%)

0/92

(0%)

N. flavescens

3/15

(20%)

0/15 (0.0%)

1/13 (7.7%)

1/13 (7.7%)

2/13 (15.4%)

5/13 (38.5%)

0/13

(0%)

N. macacae

3/6

(50%)

0/6

(0.0%)

0/6 (0.0%)

3/6

(50%)

3/6

(50%)

2/6 (33.3%)

0/6

(0%)

N. mucosa

1/3 (33.3%)

0/3 (0.0%)

0/3 (0.0%)

0/3

(0.0%)

0/3

(0.0%)

0/3 (0.0%)

0/3

(0%)

N. perflava

4/10

(40%)

1/10

(10%)

0/9 (0.0%)

1/9 (11.1%)

1/9 (11.1%)

2/9 (22.2%)

0/9

(0%)

N. subflava

15/59 (25.4%)

4/59 (6.8%)

3/58 (5.1%)

10/58 (17.2%)

15/58 (25.9%)

15/58 (25.9%)

0/59

(0%)

Neisseria spp (NO ID)

1/7

(14.2%)

0/7

(0.0%)

0/3 (0.0%)

0/3

(0.0%)

0/3

(0.0%)

3/3

(100%)

0/2

(0%)

 

EUCAST NR/NT (%)

PEN

CRO

CFX

CIP

TET

AZI*

GEN§

Breakpoint (R >)

1

0.125

0.125

0.06

0.5

1

16

Overall

27/101 (26.7%)

13/100 (13%)

5/92 (5.4%)

42/92 (45.7%)

34/92 (37%)

27/92 (29.3%)

0/92

(0%)

N. flavescens

3/15

(20%)

3/15

(20%)

1/13 (7.7%)

6/13 (46.2%)

5/13 (38.5%)

5/13 (38.5%)

0/13

(0%)

N. macacae

3/6

(50%)

1/6 (16.7%)

1/6 (16.7%)

6/6 (100%)

4/6 (66.7%)

2/6 (33.3%)

0/6

(0%)

N. mucosa

1/3 (33.3%)

0/3

(0.0%)

0/3 (0.0%)

1/3 (33.3%)

0/3

(0.0%)

0/3

(0.0%)

0/3

(0%)

N. perflava

4/10

(40%)

2/10

(20%)

0/9 (0.0%)

4/9 (44.4%)

2/9 (22.2%)

2/9 (22.2%)

0/9

(0%)

N. subflava

15/59 (25.4%)

6/59 (10.1%)

3/58 (5.1%)

24/58 (41.3%)

23/58 (39.7%)

15/58 (25.9%)

0/59

(0%)

Neisseria spp (NO ID)

1/7

(14.2%)

1/7 (14.2%)

0/3 (0.0%)

1/3

(33.3%)

0/3

(0.0%)

3/3

(100%)

0/2

(0%)

N. gonorrhoeae (%R)‡

17.9

0

0.8

42.7

62.9

4.2

n/a

  1. NR, number of resistant isolates; NT, total number of isolates tested; n/a, not applicable.
  2. PEN; penicillin, CRO; ceftriaxone, CFX; cefixime, CIP; ciprofloxacin, TET; tetracycline, AZI; azithromycin; GEN; gentamicin.
  3. *Azithromycin based on ECOFF of S < 1 mg/L, §Gentamicin based on previous recommended breakpoint27.
  4. ‡Data from Gonococcal Resistance to Antimicrobials Surveillance Programme, 202028.
Back to article page